Eisai Withdraws Application for Additional Indication of Aricept
for Treatment of Severe Alzheimer's Disease in Europe
TOKYO, April 13, 2007-Eisai Limited (Headquaters: London, Managing
Director: Paul Hooper), the U.K. subsidiary of Eisai Co., Ltd.
(Headquarters: Tokyo, President & CEO: Haruo Naito), today
announced that the company has tentatively withdrawn its
application for an additional indication for Aricept® in the
treatment of severe Alzheimer's disease, submitted through the
mutual recognition procedure in Europe. Eisai will discuss the
matter with the European regulatory authorities and review
possibilities for resubmission.
The Aricept®'s indication in the treatment of severe
Alzheimer's disease has already been approved in the USA, India,
New Zealand and Philippines. In addition, the application has been
submitted in Japan.
Eisai will continue to undertake activities to help patients who
are suffering from Alzheimer's disease.
Corporate Communications Department
Eisai Co., Ltd.
Posted: April 2007